Research and development continues long after a medicine is initially approved

The government’s flawed price setting plan under the Build Back Better Act will significantly upend the biopharmaceutical research and development (R&D) process, risking important advances in patient...
Read More
Four things to know from IQVIAs latest report

As the debate in Washington continues on drug pricing, it’s important that policymakers take into account what is actually happening in the market for medicines. Here are four things about medicine...
Read More
H.R. 3 threatens access to medicines, future innovation and American jobs

In the last election, voters made clear that they want quality, affordable health coverage that works when they need it and lower out-of-pocket costs for medicines. And we can achieve those goals,...
Read More
New analysis finds stark difference in coverage of breast cancer medicines for seniors in the United States and England

In the United States, seniors and people with disabilities enjoy broad coverage of physician-administered medicines under Medicare Part B because the program relies on market competition to balance...
Read More
No matter how you look at it, the Most Favored Nation rule is bad policy

Last month, the administration released the “Most Favored Nation” (MFN) rule, which allows foreign governments to decide the value of Part B medicines, while also likely limiting seniors’ access to...
Read More
Learning from history: How government price setting and other anti-innovation policies negatively impact biopharmaceutical R&D

Today, America leads the world in medical innovation because of our unique research ecosystem, but that wasn’t always the case. A new paper from NDP Analytics, “Will US Leadership in...
Read More
ICYMI: The latest as America’s biopharmaceutical companies work to beat COVID-19

America’s biopharmaceutical companies are working around the clock to defeat COVID-19, a disease caused by a novel strain of the coronavirus. The biopharmaceutical industry continues to make...
Read More
Executive order threatens R&D when we need it most to fight COVID-19

In case you missed it, President Trump recently signed executive orders that would implement sweeping changes to the biopharmaceutical industry. While his intention may have been to help Americans...
Read More
The continued imperative to protect U.S. innovation worldwide

The COVID-19 pandemic is further demonstrating that the world needs biopharmaceutical innovation to address pressing global health challenges – both now and in the future. PhRMA members are...
Read More
Three reasons the Administration should abandon its International Pricing Index proposal

According to the Council of Economic Advisers, “Heavy-handed government intervention may reduce drug prices in the short term, but these savings are not worth the long-term cost of American patients...
Read More